That is the question any prudent investor would as
Post# of 36536
There is a catch. We just don't know where the market will place it as of yet. My guess would be NGIO gets some credit but Generex may not see anywhere near the full value of it ownership %. Not uncommon for "holding companies" to be undervalued vs their assets.
Obviously news could change that perspective in a New York minute. Big pharma deals can make thousandaires into hundred thousandaires and sometimes millionaires in an instant.